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Abstract
Background: The androgen receptor is a ligand-induced transcriptional factor, which plays an
important role in normal development of the prostate as well as in the progression of prostate
cancer to a hormone refractory state. We previously reported the identification of a novel AR
coactivator protein, L-dopa decarboxylase (DDC), which can act at the cytoplasmic level to
enhance AR activity. We have also shown that DDC is a neuroendocrine (NE) marker of prostate
cancer and that its expression is increased after hormone-ablation therapy and progression to
androgen independence. In the present study, we generated tetracycline-inducible LNCaP-DDC
prostate cancer stable cells to identify DDC downstream target genes by oligonucleotide
microarray analysis.
Results: Comparison of induced DDC overexpressing cells versus non-induced control cell lines
revealed a number of changes in the expression of androgen-regulated transcripts encoding
proteins with a variety of molecular functions, including signal transduction, binding and catalytic
activities. There were a total of 35 differentially expressed genes, 25 up-regulated and 10 down-
regulated, in the DDC overexpressing cell line. In particular, we found a well-known androgen
induced gene, TMEPAI, which wasup-regulated in DDC overexpressing cells, supporting its known
co-activation function. In addition, DDC also further augmented the transcriptional repression
function of AR for a subset of androgen-repressed genes. Changes in cellular gene transcription
detected by microarray analysis were confirmed for selected genes by quantitative real-time RT-
PCR.
Conclusion: Taken together, our results provide evidence for linking DDC action with AR
signaling, which may be important for orchestrating molecular changes responsible for prostate
cancer progression.
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Prostate cancer is the most commonly diagnosed invasive
male cancer in North America and in other Western coun-
tries [1]. In most cases prostate cancer begins as an andro-
gen-dependent tumor that undergoes clinical regression
in response to pharmacological and surgical strategies that
reduce testosterone concentration. This form of therapy is
generally used to treat advanced cancer or those that recur
after radiation or surgical procedures to remove the pri-
mary cancer. Despite androgen withdrawal therapy most
patients develop lethal androgen-independent (AI)
tumors [2,3]. At present, no effective therapy is available
for this latter group of patients [4]. The underlying molec-
ular mechanism involved in androgen-independent pros-
tate cancer and the therapies aimed at this are the active
areas of current research.
The actions of androgen within the prostate are mediated
by the androgen receptor (AR), a member of the nuclear
receptor family of ligand-activated transcription factors
[5]. Upon binding hormone, AR binds to androgen
response elements in androgen receptor-responsive pro-
moters, recruits multiple coregulators, and activates tran-
scription of androgen-regulated genes involved in cell
growth and survival [4,6,7]. In the majority of AI tumors,
AR continues to be expressed and seems to be activated
under androgen-depleted conditions [8]. Alterations in
AR or the AR signaling pathway are potential explanations
for progression to androgen independence [9,10]. A large
number of coactivators and corepressors involved in the
regulation of AR-driven transcription have been identified
[11]. They function as signaling intermediaries between
AR and general transcriptional machinery. Furthermore,
an increase in coactivator levels has been shown in AI dis-
ease [12-16]. Coactivator proteins have been shown to
enhance the activity of AR through a variety of mecha-
nisms, including use of alternative ligands, sensitization
of the receptor to lower levels of androgens, and ligand-
independent activation [14,17].
Using the repressed transactivator (RTA) yeast two-hybrid
system, we previously identified a novel AR-coactivator
protein, L-dopa decarboxylase (DDC) [18], also referred
to as aromatic L-amino acid decarboxylase (AADC). DDC
is responsible for decarboxylating both L-dopa and L-5-
hydroxytryptophan into dopamine and serotonin, respec-
tively [19]. The human gene encoding the L-dopa decar-
boxylase enzyme, referred to as DDC, maps to
chromosome band 7p11 and is composed of 15 exons
spread out over at least 85 kb of genomic DNA [20]. DDC
is widely distributed in neural tissues, where it plays a
neuron-specific role as a neurotransmitter biosynthetic
enzyme, and in non-neuronal tissues (adrenals, kidney,
liver, gastrointestinal tract and lungs), where it acts as a
non-specific decarboxylating enzyme and may have other
undetermined functions [21]. Our recent studies using tis-
sue microarrays and dual immunofluoresence indicate
that in prostate cancer, DDC is not only a neuroendocrine
(NE) marker, but is also co-expressed with AR in a subset
of NE tumor cells [22]. DDC-positive prostate cancer cells
show a dramatic increase in number after extended peri-
ods of neoadjuvant hormone withdrawal (> 6 months)
and in metastatic tumors that have progressed to the AI
phenotype [22]. The enhancement of AR transactivation
by DDC is likely restricted to the AR-positive subset of NE
cells. The mechanism of DDC-mediated regulation of AR
signaling in prostate carcinogenesis remains unknown,
but may involve sensitization of AR to limiting concentra-
tion of androgen [18].
In the past few years, newly developed technologies such
as gene microarrays [23] have enabled the determination
of molecular differences between normal and trans-
formed cells at the genome wide-level. Microarrays have
been used to study androgen regulated genes involved in
the development of prostate cancer [24], and to character-
ize molecular function of AR or other steroid receptor
interacting proteins [25-27]. In particular, microarray
analysis has been used to better define the molecular func-
tion of Ebp1 protein, an AR corepressor [25], and to study
AIB1 protein, a steroid receptor coactivator [27], as well as
to characterize a novel modulator of AR activity, the male
germ cell-associated kinase (MAK) [26]. These studies sug-
gest that microarray analysis is a useful means for studying
the effects on gene expression of steroid receptor interact-
ing proteins. Here, in an effort to better understand the
molecular function of DDC as a coactivator of AR-medi-
ated signaling and to identify novel targets of prostate car-
cinogenesis, we evaluated the effects of regulated DDC
expression in an inducible manner in LNCaP cells using
gene microarray analysis.
Results
Inducible expression of DDC in LNCaP human prostate 
cancer cells
The identification of AR-regulated genes that are affected
by DDC overexpression may provide important clues
regarding the biology of this catecholamine synthesis
enzyme and its influence on AR function. Toward this
end, the change in gene expression of androgen-regulated
genes caused by sustained DDC overexpression were ana-
lyzed in vitro by the generation of LNCaP cells stably
expressing Dox-inducible DDC. We used human andro-
gen-dependent prostate cancer cells (LNCaP), since our
primary goal was to assess the co-activation function of
DDC, known to enhance AR activity through an andro-
gen-dependent mechanism [18]. To verify the effects of
Dox treatment on expression of the DDC gene, LNCaP
cells, stably expressing Dox-inducible DDC (LNCaP-
DDC) or the vector control (LNCaP-pDEST) were treatedPage 2 of 11
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induced (+Dox) conditions. With Dox treatment, we
observed an optimal 6-fold increase in DDC protein levels
when compared with mock-induced (-Dox) LNCaP-DDC
cells. No detectable DDC protein was found under the
Dox-induced (+Dox) or mock-induced (-Dox) condition
in the LNCaP-pDEST cell line, confirming the fact that
endogenous DDC protein expression levels in this cell
line are below detection when directly compared to
ectopic overexpression (Figure 1A) [18]. To investigate the
extent of DDC overexpression at the RNA level, we com-
pared by RT-PCR the mRNA levels in DDC overexpressing
cells, with the vector control cells after Dox stimulation. In
the LNCaP-DDC cells, higher levels of DDC mRNA were
observed than in the vector control LNCaP-pDEST cells,
where only a faint band was detected (Figure 1B).
Influence of DDC on the androgen-regulated gene 
expression profile
The availability of the LNCaP-DDC cell line afforded us
an opportunity to study the influence of DDC overexpres-
sion on global gene expression using the Human Operon
21 K oligonucleotide array. Our goal in this study was to
identify which genes among the AR-regulated genes, are
affected by DDC overexpression. We prepared total RNA
from DDC overexpressing cells (LNCaP-DDC) and from
the LNCaP control cell lines (LNCaP-DDC-Dox, LNCaP-
pDEST- Dox, and LNCaP-pDEST+Dox) after 48 h treat-
ment with or without Dox, 24 h of which was in the pres-
ence or absence of R1881 synthetic hormone (Figure 2).
Independent probe synthesis from different batches of
RNA and hybridizations were performed in duplicate. To
account for dye bias a dye swap was also performed. To
identify the androgen-regulated genes in both LNCaP-
DDC and LNCaP control cells, total RNA isolated from
hormone treated (+R1881) samples was combined with
total RNA isolated from hormone-untreated (-R1881)
samples and the relative abundance of each gene was cal-
culated as a ratio between hormone-treated and hor-
mone-untreated samples. The data set was normalized,
and a filter was applied to select only those genes whose
expression level was significant (p ≤ 0.05) in at least 1 out
of the 2 conditions. A total of 3,127 genes were identified,
and presented as a scatter correlation plot in Figure 3.
Genes that showed significant expression levels across cell
types (p ≤ 0.05) were further analyzed to characterize
those genes whose expression levels were increased or
repressed by at least 2-fold during hormone treatment (±
R1881). Genes showing an expression level > 0.5 and < 2
were classified as unchanged and not considered further.
In this study, we focused on those genes that were hor-
mone up-or down-regulated in both LNCaP-DDC and
LNCaP control cells.
LNCaP-DDC cell line displays regulated DDC expression with Dox treatmentFigure 1
LNCaP-DDC cell line displays regulated DDC expression with Dox treatment. Shown are the results from (A) 
Western blot and (B) semiquantitative RT-PCR analysis of the expression of DDC protein and mRNA, respectively. In A, 
LNCaP-DDC and LNCaP-pDEST (vector control) cells were treated for 48 hours under mock-induced (-Dox) and Dox-
induced (+Dox) conditions before protein lysate preparation. No visible expression was detected in the LNCaP-pDEST con-
trol cells regardless of Dox treatment status (lines 3–4). A 6 fold increased DDC expression level was detected in the Dox-
induced LNCaP-DDC cells compared to the mock-induced cells (lines 1–2), after β-actin normalization. In B, total cellular 
RNA was isolated from LNCaP-DDC and LNCaP-pDEST cells after 48 hours of Dox treatment. After reverse transcription, 
PCR was performed with DDC and β-actin specific primers. The up-regulation of the 209-bp DDC-specific band was detected 
in LNCaP-DDC cells (line 2). A 100 bp DNA ladder (Promega) was used for size markers.
A           B Page 3 of 11
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Venn diagram analysis, 130 genes that were androgen-reg-
ulated in LNCaP-DDC and LNCaP control cells (Figure
4A). The hormone induction response of these 130 genes
was substantiated by the altered expression of the classi-
cally androgen-regulated genes, such as PSA, FKBP5,
NKX3A, TMEPAI, KLK2, ODC1, and TMPRSS2 (data not
shown). Comparison of LNCaP-DDC and LNCaP control
cells revealed a number of changes in the expression pro-
file of these androgen-regulated genes. Out of the 130
genes, 35 were differentially regulated as shown in Table
1. Of these, 25 genes were up-regulated at least two fold
and 10 were down-regulated by at least two fold with
DDC overexpression. In particular, among the set of 35
genes, we could identify four different responses to hor-
mone treatment and DDC overexpression: i) 2 genes were
hormone and DDC up-regulated ii) 4 genes were hor-
mone and DDC down-regulated iii) 23 genes were hor-
mone down-regulated in control cells and hormone up-
regulated in DDC overexpressing cells iv) 6 genes were
hormone up-regulated in control cells and hormone
down-regulated in DDC overexpressing cells (Figure 4B).
Gene ontology classification of these 35 differentially
expressed genes was performed by using GeneBank acces-
sion number, Operon ID, and annotation tools database
available on-line [28,29]. The gene sets were classified
according to their putative main molecular function.
While the list of 35 genes contained 15 unclassified tran-
scripts, of the remaining 20, ontological molecular func-
tion analyses revealed signal transducer, binding, and
catalytic activity as the predominant divergences between
DDC overexpressing cells and controls (Table 1). Gene
ontology classifications with overlapping gene lists were
combined. The signal transducer classification defines
those transcripts that mediate the transfer of a signal from
the outside to the inside of a cell by a means other than
Microarray analysis of DDC-regulated genesFigure 2
Microarray analysis of DDC-regulated genes. Experi-
mental outline of microarray studies to identify DDC down-
stream targets using LNCaP-DDC stable and control 
LNCaP-pDEST cells. In the presence of Dox (grey triangle, + 
Dox) the tetracycline Tet repressor (tetR) is released from 
the TetO2 sequence in the promoter of the lentiviral con-
struct containing the DDC gene. The dissociation of the tetR 
allows induction of transcription for the gene of interest. 
LNCaP-DDC and LNCaP-pDEST (vector control) cell lines 
were plated in medium containing 5% charcoal-stripped 
serum and incubated overnight. The next day, cells were 
treated for 48 hours under mock-induced (-Dox) and Dox-
induced (+Dox) conditions, 24 h of which was in the pres-
ence or absence of 0.1 nM R1881. Total RNA samples were 
isolated from each condition, labeled and hybridized on the 
microarrays. The relative mRNA abundance of each gene 
was calculated as a ratio between hormone-treated 
(+R1881) and hormone-untreated (- R1881) samples. The 
comparison of the expression data obtained from LNCaP-
DDC+Dox stable cells (left) with the expression data from 
the three LNCaP control cells (right: LNCaP-DDC-Dox, 
LNCaP-pDEST- Dox, and LNCaP-pDEST+Dox) yielded the 
identification of genes that are androgen- and DDC-regu-
lated.
Scatter plot of entire gene set considered expressed (p val-ues = 0.05) in the microarray analysisFigure 3
Scatter plot of entire gene set considered expressed 
(p values = 0.05) in the microarray analysis. The posi-
tion of each dot on the scatter plot corresponds to the nor-
malized average signal intensity (log scale) of a single gene. 
The normalized average signal intensity under the DDC 
overexpression conditions are shown on the x and y axes 
(controls = no DDC overexpression and DDC = DDC over-
expression). The middle line indicates values that represent a 
DDC/controls ratio of 1.0 (similar levels of expression in 
both cell lines). The outer lines represent a DDC/controls 
ratio of 2.0 (upper line; 2-fold greater expression in DDC 
compared to controls) and of 0.5 (lower line; 2-fold greater 
expression in controls compared to DDC).Page 4 of 11
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The binding activity category defines those transcripts
encoding for proteins capable of selective, often stoichio-
metric, interaction with one or more specific sites on
another protein. The catalytic activity group refers to those
proteins able to perform the catalysis of a biochemical
reaction. Further annotation analysis of the transcripts
involved in signal transduction, subclassified four genes
into the G-protein-coupled receptors (GPCRs) signaling
pathway (DRD3, PTGDR, GPR15, and GABRE). Interest-
ingly, we found a 4.3-fold down-regulation of the DRD3
gene in DDC overexpressing cells when compared with
controls. The DRD3 gene encodes the D3 subtype
dopamine receptor which binds dopamine, one of the
enzymatic products of DDC [30]. The D3 receptor, along
with the other GPCRs, are known to modulate a plethora
of signal transduction pathways that can cross-talk with
known AR activation pathways [4]. Among the genes up-
regulated by DDC overexpression, there was a well estab-
lished androgen regulated TMEPAI gene [31,32] (Table
1). Another gene up-regulated by DDC overexpression
was TGM2, which belongs to the transglutaminase
(hTGP) enzyme family (EC 2.3.2.13) [33]. Interestingly,
the expression of one of these family members, prostate
transglutaminase enzyme (TGM4), has been shown to be
androgen-regulated [34]. SYTL2 was among the androgen
down-regulated genes, and has been previously shown to
be differentially regulated by AR reduction in prostate
cancer cells [35]. Overall, our results indicated that 35
genes were differentially expressed after induced overex-
pression of DDC in LNCaP cells, including genes known
to be up- or down-regulated by AR.
Verification of microarray results by quantitative RT-PCR
To verify the results of our microarray analyses, we
selected seven representative genes from the list in Table 1
and determined their expression profiles by quantitative
real-time RT-PCR. TMEPAI, SYTL2, TGM2, DRD3, and
PTGDR were chosen because of the above consideration,
whereas UNC5C and YME1L1 genes were selected based
on the large magnitude of change (Table 1) and GAPDH
was used as an endogenous control. The same RNA sam-
ples used for the microarray hybridization were exam-
ined. For simplicity we did not consider the mock-
induced (-Dox) samples, but compared the RNA extracted
from LNCaP-DDC Dox-induced cells (+Dox) versus the
RNA extracted from the empty vector LNCaP-pDEST Dox-
induced cells (+Dox). Although the magnitudes of up-or
down-regulation of the TMEPAI, SYTL2, TGM2, DRD3,
YME1L1 and PTGDR genes in the array analysis were dif-
ferent than that observed by real time RT-PCR, there was
a similar trend in the changes with respect to both R1881
treatment and DDC overexpression (Table 2). A constant
level of GAPDH was observed. Unfortunately no voluble
template was obtained for the UNC5C gene. Overall, the
Table 1: Differentially expressed genes in response to DDC 
overexpression*. The genes shown here are those whose 
expressions are increased (≥ 2) or decreased (≤ -2).
Genbank Acc Gene Symbol & Name DDC/CTRLs
Binding
BC016658 E2F7; E2F transcription factor 7 -13.60
AK024500 MICAL1; microtubule associated 
monoxygenase
+7.92
BC009212 MTA1; metastasis associated 1 +9.50
NM_032943 SYTL2; synaptotagmin-like 2 -2.02
AK027128 ZNF277; zinc finger protein 277 -3.88
AK054916 ZNF333; zinc finger protein 333 +4.67
AK056666 ZNF488; zinc finger protein 488 +6.76
Binding and catalytic activity
NM_019885 CYP26B1; cytochrome P450, family 
26, subfamily B, polypeptide 1
+4.29
NM_022819 PLA2G2F; phospholipase A2, group 
IIF
+30.10
NM_004613 TGM2; transglutaminase 2 +2.10
AK022930 YME1L1; YME1-like 1 (S. 
cerevisiae)
+21.40
Binding and signal transducer activity
NM_000796 DRD3; dopamine receptor D3 -4.28
U92285 GABRE;Gamma-aminobutyric acid 
(GABA) A receptor, epsilon
+10.02
NM_004532 MUC4; mucin 4, tracheobronchial -6.39
AF070577 OPCML; opioid binding protein/cell 
adhesion molecule-like
-3.87
NM_003728 UNC5C; unc-5 homolog C (C. 
elegans)
+18.48
Catalytic activity
AK055136 C2orf11; chromosome 2 open 
reading frame 11
+5.79
AK054688 PON2; paraoxonase 2 +6.99
Signal transducer activity
NM_005290 GPR15; G protein-coupled receptor 
15
+7.47
AK026202 PTGDR; prostaglandin D2 
receptor (DP)
+5.26
Unclassified
AL110152 CD109; CD109 antigen (Gov platelet 
alloantigens)
+6.20
NM_006408 AGR2; anterior gradient 2 homolog 
(Xenopus laevis)
-5.31
NM_004312 ARR3; arrestin 3, retinal (X-arrestin) -8.08
NM_032149 C4orf17; chromosome 4 open 
reading frame 17
-6.81
AK024536 CADPS; Ca2+-dependent secretion 
activator
+8.45
BC015117 DEPDC4; DEP domain containing 4 +7.83
AK057372 FLJ32810; hypothetical protein 
FLJ32810
-14.32
AF305616 TMEPAI; transmembrane, 
prostate androgen induced 
RNA
+2.06
AK025272 Unkown +15.27
AK021730 Unkown +31.81
AF130053 Unkown +23.33
AL080106 Unkown +4.04
AK021569 Unkown +16.22
AK001133 Unkown +7.59
AK055083 Unkown +6.91
*Bold indicated genes investigated further by RT-PCRPage 5 of 11
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studies.
Discussion
Our laboratory has shown that DDC is a coactivator of AR
[18] and a neuroendocrine marker of prostate cancer that
increases in expression during hormone-ablation therapy
and after progression to AI [22]. Coregulator proteins play
a crucial role in modulating transactivation of AR and
consequently may be important in regulating aberrant
activity of AR during prostate cancer progression. In this
study, we explored the effect of overexpression of DDC on
the gene expression profile of an androgen-dependent
prostate cancer cell line. We employed a tetracycline-regu-
lated system to inducibly overexpress DDC and screen for
potential downstream target genes in LNCaP cells using
an oligonucleotide array with 21 K individual human
genes. In particular, we first selected a list of genes that
were androgen-regulated regardless of DDC status. To this
end, in both DDC overexpressing and control cells, we
selected all the genes that were significantly expressed (p ≤
0.05) and which displayed at least a 2 fold increased or
decreased expression due to hormone treatment (±
R1881). Our interest was then focused on the identifica-
tion of those genes that were differentially regulated by
DDC overexpression.
Comparison of DDC overexpressing cells (LNCaP-DDC)
versus controls cells revealed a number of changes in the
expression of androgen-regulated transcripts encoding
proteins with a variety of molecular functions, including
signal transduction, binding and catalytic activities.
Androgen-regulated and DDC-regulated genesFigure 4
Androgen-regulated and DDC-regulated genes. A) A Venn diagram analysis showing in yellow, the genes (130) with 
two fold induction in response to R1881 treatment in DDC overexpressing and control cells. The genes up- and down-regu-
lated only in DDC overexpressing cells are represented in red (DDC; left) and the genes up- and down-regulated only in the 
control cells are represented in the green (controls; right). B) Reported here are 35 androgen-regulated genes differentially 
expressed at least 2-fold in DDC overexpressing cells (LNCaP-DDC) compared with the controls cells (LNCaP-CTRLs). The 
colors represent the ratio of gene expression levels in each cell line after R1881 treatment (red = hormone up-regulated and 
green = hormone down-regulated).Page 6 of 11
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tate-specific antigen (PSA), was on the chip and was found
in the hormone up-regulated genes group, it did not show
any significant difference in gene expression levels when
DDC was overexpressed. This may be due to the possibil-
ity that PSA expression is not DDC-specific or long-term
(> 2 days) overexpression of DDC, may be required to
increase PSA expression. This was not entirely unexpected
since most classical coactivators, such as SRC/p160 family
members, have not been reported to increase androgen-
induced expression of endogenous PSA in LNCaP cells.
In this study, 25 up-regulated and 10 down-regulated
genes were identified in DDC overexpressing cells com-
pared with control cells (Table 1). Real-time RT-PCR con-
firmed and validated the microarray gene expression data.
The difference in magnitude observed between microarray
findings and quantitative RT-PCR is likely due to different
technique efficiency and/or primers specificity (Table 2).
Among the genes that were hormone and DDC up-regu-
lated, there was a well established androgen regulated
gene,TMEPAI [31]. In a previous study, evaluation of
TMEPAI (also referred to as PMEPA1) expression in
LNCaP cells demonstrated induction by androgen in a
time- and dose-dependent manner. Interestingly, the
authors also showed that TMEPAI was overexpressed in AI
tumors when compared with androgen sensitive tumors
[31]. Another gene found to be hormone and DDC up-
regulated is the TGM2 gene, which belongs to the trans-
glutaminases (TGases) family (EC 2.3.2.13) [33]. The
transglutaminases are calcium-dependent enzymes cata-
lyzing the post-translational cross-linking of proteins.
Even though no direct androgen regulation has been
reported for the TGM2 gene, another transglutaminase
enzyme (TGM4) has been found to be androgen regulated
in human prostate cancer cell lines [34]. Androgen and
DDC induced expression of TMEPAI and TGM2 may rep-
resent direct evidence of the androgen-dependent co-acti-
vation function of DDC on AR.
Among the hormone and DDC down-regulated genes was
the SYTL2 gene, which was previously shown to be posi-
tively regulated by AR reduction in androgen-ablated
prostate cancer cells [35]. In particular, a 2 fold up-regula-
tion of the SYTL2 gene was found after 48 h reduction of
AR [35], demonstrating that SYTL2 is normally an andro-
gen-repressed gene. In our study, overexpression of DDC
further reduced the expression of SYTL2, suggesting that
this AR-binding protein may also augment the repressive
transcriptional function of AR. The SYTL2 gene encodes
for the vesicular transport protein synaptotagmin 2,
which regulates exocytosis of synaptic vesicles and
appears to serve as a calcium sensor to trigger neurotrans-
mitter release [36]. A possible explanation of this finding
could be related to the increased synthesis of neurotrans-
mitters produced by DDC inside the cell, and subsequent
negative feedback on these vesicular transporter related
proteins.
Among the genes differentially regulated in DDC overex-
pressing cells, were four genes encoding GPCR proteins
(DRD3, PTGDR, GPR15, and GABRE). The GPCRs share
significant structural homology [37,38] and are known to
modulate numerous of signal transduction pathways that
can cross-talk with known AR activation pathways [4]. A
general model for GPCR activity has been postulated
where GPCRs are in equilibrium between active and inac-
tive states, and that interaction with a GPCR agonist, sta-
bilizes a conformational change in these receptors which
in turn promote signal generation inside the cell [39].
Recently, it has been shown that transition of prostate
cancer to the AI stage is associated with increased expres-
sion of GPCRs [40-42]. Furthermore, in vitro stimulation
of endogenous GPCRs (e.g. LPA, B1R) induces mitogenic
signaling and growth of AI prostate cancer [42-44]. Pros-
tate cancers also express elevated levels of GPCR ligands,
which may contribute to progression of disease
[40,41,45]. Therapies targeting GPCRs represent the sin-
gle largest drug class [46], suggesting that they may be
effective in limiting pathologic growth of the prostate.
Table 2: Confirmation of microarray findings by real-time RT-PCR*
R1881 ± R1881 ± 
Symbol ARRAY DDC ARRAY controls RT-PCR DDC RT-PCR control ARRAY DDC/controls RT-PCR DDC/control
TGM2 4.7 2.2 36.7 25.2 +2.1 +1.5
TMEPAI 4.8 2.3 17.8 10.6 +2.1 +1.7
PTGDR 2.2 0.4 1.5 0.5 +5.3 +3.0
YME1L1 2.6 0.1 1.3 0.8 +21.4 +2.5
SYTL2 0.3 0.5 0.2 0.3 - 2.0 - 1.5
DRD3 0.1 0.3 0.5 0.9 - 4.3 - 1.8
* In bold are represented the fold changes of hormone up-regulated genes and in italic the fold changes of hormone down-regulated genes, after 
R1881 treatment. The symbols +/- indicate the fold induction (+) or repression (-) due to DDC overexpression.Page 7 of 11
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between prostate cancer progression and increased expres-
sion levels of PTGDR, GPR15, and GABRE genes. In con-
trast, the DRD3 gene was found to be down-regulated in
DDC overexpressing cells when compared with control
cells. The DRD3 gene encodes the D3 subtype dopamine
receptor for which the DDC neurotransmitter product,
dopamine, is an agonist. D3 receptor is classified as a
member of the D2-like dopamine receptor family, which
also includes the D2 and D4 dopamine receptor subtypes
[47,48]. Interestingly, it has been shown that D2-like
receptors can modulate many signal transduction path-
ways (e.g. MAPK, PKA, PKC) [49-51] that are also known
to stimulate AR activation [4,52,53]. Altered regulation of
this receptor in prostate cancer cells could lead to indirect
activation of the AR signaling pathway. Since D2-like
receptors can mediate inhibition of cAMP and PKA signal-
ing [51], one can speculate that in the presence of
dopamine, decreased expression of the D3 receptor sub-
type could reduce its inhibitory effect on the cAMP and
PKA pathways when DDC is overexpressed. This may
result in high level activation of PKA signaling that can
enhance AR activity [4]. Overall, the altered expression of
GPCRs by DDC may result in increased mitogenesis and
growth of prostate tumors.
Conclusion
This study demonstrates that overexpression of the DDC
gene in the LNCaP cells leads to differential expression of
a total of 35 genes. More detailed studies examining the
association between the AR-DDC interaction and these
genes are necessary to better understand the functional
relationships. Potentially all these putative hormone-reg-
ulated genes are directly or indirectly downstream targets
of DDC and they may be important for orchestration of
molecular changes that are responsible for prostate cancer
progression. Also since DDC expression increases with
long-term neo-adjuvant hormone therapy (> 6 months)
and in metastatic tumors that have progressed to the AI
phenotype [22], future studies could utilize castrated
(hormone-deprived) mice in the LNCaP xenograft model
as an in vivo experimental system for monitoring the
potential effects of DDC on the expression profile of genes
associated with growth, regression, and progression to AI.
Methods
LNCaP cells expressing tetracycline-inducible DDC
LNCaP cells stably expressing tetracycline-inducible DDC
(LNCaP-DDC) were generated using ViraPower T-REx
Lentiviral Expression System and Gateway Technology
vectors, according to the manufacturer's protocol (Invitro-
gen) (Wafa LA, 2007 manuscript in preparation). Briefly, 3
μg of each lentiviral vector, pLenti4/TO/V5-DEST carrying
the DDC gene or the empty vector pLenti4/TO/V5-DEST
and the pLenti6/TR containing the TetR gene, together
with 9 μg of the ViraPower packaging mix, were trans-
fected into 293T cells, using Lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA). The DNA- Lipofectamine
2000 complexes diluted in Opti-MEM I Medium (Gibco-
BRL) were allowed to form for 20 min at room tempera-
ture before addition to 293T cells. Cells were maintained
for 24 hours at 37°C and 5% CO2 before removing the
media containing the DNA-Lipofectamine 2000 com-
plexes and replacing with DMEM media (10% FBS, 2 mM
L-glutamine, 0.1 mM MEM Non-Essential Amino Acids,
1% penicillin/streptomycin, and 1 mM MEM Sodium
Pyruvate).
Resulting retroviral particles were harvested by removing
medium 72 hours after transfection and used to generate
a stably co-transduced LNCaP cell lines. Two cell lines
were created: the LNCaP-DDC line, which expresses tetra-
cycline-inducible DDC, and the LNCaP-pDEST line,
which contains the empty vector control and the tetR
gene. To induce tetracycline-regulated DDC expression 1
μg/ml of doxycycline hyclate (Dox) (Sigma-Aldrich) was
added to the cell culture media.
RNA isolation and expression profiling
LNCaP-DDC, and LNCaP-pDEST cell lines were plated in
10-cm plates (2 × 106 per plate) in RPMI 1640 containing
5% charcoal-stripped serum (CSS; HyClone, VWR, West
Chester, PA). When the cells reached 60% confluence,
they were seeded in presence of 1 μg/ml of Dox (Dox-
Table 3: Primers for real time RT-PCR analysis
Gene Forward primer Reverse primer
TMEPAI TGCCGTTCCATCCTGGTT AGACAGTGACAAGGCTAGAGAAAGC
YME1L1 GAGCTTGGACACAACCGATAACT CCGCAGTGTACAGGGATTGA
SYTL2 TCTGCCTTGAGAAAACAAACAGTT GCCAGTGGGTGGCACTAAAA
UNC5C GGCCGTCCAGGTGAATCA TGCATTCTTGCCTGTGAAGTG
TGM2 TCTCTGGGCCTTTGTTTCCTT GATCCTTGGAGATGAGCTGGTT
PTGDR TCAGGACTCCAAGGTGCAAAG TCTGGCTGGAGGTCTTGAGATC
DRD3 GAATTCCCTGAGTCCCACCAT CCATTGCTGAGTTTTCGAACTTC
GAPDH GAAGGTGAAGGTCGGAGT GAAGATGGTGATGGGATTTCPage 8 of 11
(page number not for citation purposes)
Molecular Cancer 2007, 6:38 http://www.molecular-cancer.com/content/6/1/38induced) or in the absence of Dox (mock-induced). After
24 hours the cells were stimulated with or without 0.1 nM
of synthetic androgen (± R1881) for an additional 24
hours. Total RNA was extracted using Trizol reagent by fol-
lowing the manufacturer's instructions (Invitrogen). Total
RNA from each hormone-treated sample (+R1881) was
compared with that of hormone-untreated sample (-
R1881) on the same microarray slide. Two independent
biological replicates were assayed for each sample and a
dye swap was performed to account for dye bias. Microar-
rays of 21,521 (70-mer) human oligos representing
21,521 genes (Operon Technologies, Inc., Alameda, CA)
printed on aminosilane coated microarray slides (Matrix
Technologies; Hudson, NH) were supplied by the Array
Facility of The Prostate Centre at Vancouver General Hos-
pital. Microarrays were hybridized with 10 μg of total RNA
from duplicate samples of LNCaP-DDC or LNCaP-pDEST
cells treated with or without (±) Dox, and with or without
(±) R1881, using the 3DNA Array 350™ Expression Array
Detection Kit and according to the manufacturer's instruc-
tions (Genisphere, Hatfield, PA) (Figure 2). The arrays
were immediately scanned on a Scan Array Express Micro-
array Scanner (Perkin Elmer). Signal quality and quantity
were assessed using ImaGene 7.0 software (BioDiscovery,
San Diego, CA).
Western blot analysis
The DDC antibody was purchased from Chemicon
(Chemicon Inc., Temecula, CA) and the polyclonal anti-
body to actin was obtained from Sigma (Sigma Chemical
Co., St. Louis, MO). LNCaP-DDC and LNCaP-pDEST cells
were plated in six-well plates (3 × 105 per well), treated
with Dox as described above and immunoblotted as pre-
viously reported [18]. Total cell protein (50 μg), measured
by BCA™ Protein Assay (PIRCE, Rockford, IL), was used
for immunoblotting. Band intensity was quantified using
a Bio-Rad Gel Doc 2000 software (Bio-Rad Laboratories,
USA).
Bioinformatics analysis
Raw signal data files obtained with ImaGene 7.0 software
were subsequently analyzed on GeneSpring 7.2 software
(Silicon Genetics, Redwood City, CA) for profiling signifi-
cant changes in gene expression. The fluorescent signal ratios
(+R1881/-R1881) were subjected to Lowess normalization
with background correction. Experimental error was based
on replicated dye pair values. Comparison analysis of the
gene expression data from LNCaP-DDC+Dox cells, and
LNCaP-DDC-Dox, LNCaP-pDEST-Dox, and LNCaP-
pDEST+Dox cells, treated with or without R1881, was con-
ducted to first identify androgen-regulated genes in all exper-
imental conditions, and then the differentially regulated
genes due to DDC overexpression.
Only genes with a p value of ≤ 0.05 in at least one out of two
conditions were analyzed further. Data was transformed to
log ratio (Log10) for display and analysis. All genes showing
a normalized expression value ≥ 2 or ≤ 0.5 were classified as
androgen up- or down-regulated, respectively. Genes show-
ing a normalized expression value between 0.5- and 2- were
classified as unchanged and not considered further. Lists of
androgen-regulated genes (both up-regulated and down-reg-
ulated) were created for each of the cell lines and were com-
pared by Venn diagram analysis. Genes were considered
differentially expressed as a result of DDC overexpression if
normalized values from induced LNCaP-DDC cells were at
least 2-fold greater or 2-fold less than those from the control
cells (LNCaP-DDC-Dox, LNCaP-pDEST- Dox, and LNCaP-
pDEST+Dox). Functional classifications were based on gene
ontology (GO) annotation obtained through the GeneTools
database [28,29].
Real-time quantitative RT-PCR and semiquantitative RT-
PCR
Complementary DNA (cDNA) for real time PCR and sem-
iquantitative RT-PCR was made using 2 μg of total RNA
treated with RNase-free DNase according to the manufac-
turer's instructions (Promega). First-strand cDNA was syn-
thesized using random hexamers (Perkin-Elmer Applied
Biosystems, Branchburg, NJ) with 20U of Moloneymurine
leukemia virus reverse transcriptase, M-MLV (Invitrogen).
The ABI PRISM 7700 Sequence Detection System (Perkin-
Elmer Applied Biosystems, Foster City, CA) was used for
real time monitoring of PCR amplification of cDNA. The
forward and reverse primers used for the real time RT-PCR
are listed in Table 3. All primers were selected by PRIMER
EXPRESS v.3 software and were commercially synthesized
by Integrated DNA Technologies laboratories (IDT, Cor-
alville IA). A SYBR green PCR kit was used following the
manufacturer's instructions and the analyses were per-
formed in triplicate (Invitrogen). In brief, RT-PCR ampli-
fication mixtures (25 μl) containing 25 ng template
cDNA, 2x SYBR Green I Master Mix buffer (12.5 μl), and
300 nM forward and reverse primer was prepared. Target
mRNA values were normalized using GAPDH mRNA as
an internal control. A comparative threshold cycle (Ct)
was used to determine gene expression relative to a cali-
brator. For each sample, the Ct values were calculated
using the formula ΔCT = Ct sample- Ct GAPDH. To determine
relative expression levels, the following formula was used
ΔΔCT = ΔCT sample- ΔCT calibrator and the value used to indi-
cate relative gene expression was calculated using the for-
mula 2-ΔΔCT. Primers for the semiquantitative PCR were
synthesized by Integrated DNA Technologies laboratories
(IDT, Coralville IA); DDC, sense 5'- ACA CCA TGA ACG
CAA GTG AA-3' and antisense 5'- CAC CCC AGG CAT
GAT TAT CT-3'. The PCR products (209 bp) were resolved
by electrophoresis using 1.5% agarose gels containing
ethidium bromide.
Competing interests
The author(s) declare that they have no competing inter-
ests.Page 9 of 11
(page number not for citation purposes)
Molecular Cancer 2007, 6:38 http://www.molecular-cancer.com/content/6/1/38Authors' contributions
K.M. performed the study and drafted the manuscript;
L.A.W. helped to design the study and to draft the manu-
script; H.C. helped to perform the study; G.N. critically
commented on the drafted manuscript; C.C.N partici-
pated in the design of the study and critically commented
on the drafted manuscript; P.S.R. provided overall direc-
tion for the project and revised the final version of the
manuscript; G.N., C.C.N., and P.S.R obtained funding for
the project. All authors read and approved the final man-
uscript.
Acknowledgements
We thank Robert Bell for assistance with gene expression data analysis and 
Anne Haegert for technical assistance with the microarray experiments. 
This work was supported by the Canadian Cancer Society and the National 
Cancer Institute of Canada (NCIC), and in part by funds from AIRC (Asso-
ciazione Italiana per la Ricerca sul Cancro) Regional Grant to G.N.
References
1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer
EJ, Thun MJ: Cancer statistics, 2005.  CA Cancer J Clin 2005,
55(1):10-30.
2. Klotz L: Hormone therapy for patients with prostate carci-
noma.  Cancer 2000, 88(12 Suppl):3009-3014.
3. Long RJ, Roberts KP, Wilson MJ, Ercole CJ, Pryor JL: Prostate can-
cer: a clinical and basic science review.  J Androl 1997,
18(1):15-20.
4. Feldman BJ, Feldman D: The development of androgen-inde-
pendent prostate cancer.  Nat Rev Cancer 2001, 1(1):34-45.
5. Brinkmann AO, Blok LJ, de Ruiter PE, Doesburg P, Steketee K, Ber-
revoets CA, Trapman J: Mechanisms of androgen receptor acti-
vation and function.  J Steroid Biochem Mol Biol 1999, 69:307-313.
6. Alen P, Claessens F, Verhoeven G, Rombauts W, Peeters B: The
androgen receptor amino-terminal domain plays a key role
in p160 coactivator-stimulated gene transcription.  Mol Cell
Biol 1999, 19(9):6085-6097.
7. McKenna NJ, O'Malley BW: Combinatorial control of gene
expression by nuclear receptors and coregulators.  Cell 2002,
108(4):465-474.
8. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosen-
feld MG, Sawyers CL: Molecular determinants of resistance to
antiandrogen therapy.  Nat Med 2004, 10(1):33-39.
9. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J,
Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP:
Androgen receptor gene amplification: a possible molecular
mechanism for androgen deprivation therapy failure in pros-
tate cancer.  Cancer Res 1997, 57(2):314-319.
10. Miyamoto H, Yeh S, Wilding G, Chang C: Promotion of agonist
activity of antiandrogens by the androgen receptor coactiva-
tor, ARA70, in human prostate cancer DU145 cells.  Proc Natl
Acad Sci U S A 1998, 95(13):7379-7384.
11. Janne OA, Moilanen AM, Poukka H, Rouleau N, Karvonen U, Kotaja
N, Hakli M, Palvimo JJ: Androgen-receptor-interacting nuclear
proteins.  Biochem Soc Trans 2000, 28(4):401-405.
12. Ngan ES, Hashimoto Y, Ma ZQ, Tsai MJ, Tsai SY: Overexpression
of Cdc25B, an androgen receptor coactivator, in prostate
cancer.  Oncogene 2003, 22(5):734-739.
13. Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A, Chang
C: Cloning and characterization of androgen receptor coac-
tivator, ARA55, in human prostate.  J Biol Chem 1999,
274(12):8316-8321.
14. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wil-
son EM: A mechanism for androgen receptor-mediated pros-
tate cancer recurrence after androgen deprivation therapy.
Cancer Res 2001, 61(11):4315-4319.
15. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ:
p300 in prostate cancer proliferation and progression.  Cancer
Res 2003, 63(22):7638-7640.
16. Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic
N, Krhen I, Marekovic Z, Bartsch G, Klocker H, Hobisch A, Culig Z:
The transcriptional co-activator cAMP response element-
binding protein-binding protein is expressed in prostate can-
cer and enhances androgen- and anti-androgen-induced
androgen receptor function.  Am J Pathol 2003, 162(1):233-241.
17. Scher HI, Sawyers CL: Biology of progressive, castration-resist-
ant prostate cancer: directed therapies targeting the andro-
gen-receptor signaling axis.  J Clin Oncol 2005, 23(32):8253-8261.
18. Wafa LA, Cheng H, Rao MA, Nelson CC, Cox M, Hirst M, Sadowski
I, Rennie PS: Isolation and identification of L-dopa decarboxy-
lase as a protein that binds to and enhances transcriptional
activity of the androgen receptor using the repressed trans-
activator yeast two-hybrid system.  Biochem J 2003, 375(Pt
2):373-383.
19. Berry MD, Juorio AV, Li XM, Boulton AA: Aromatic L-amino acid
decarboxylase: a neglected and misunderstood enzyme.
Neurochem Res 1996, 21(9):1075-1087.
20. Craig SP, Thai AL, Weber M, Craig IW: Localisation of the gene
for human aromatic L-amino acid decarboxylase (DDC) to
chromosome 7p13-->p11 by in situ hybridisation.  Cytogenet
Cell Genet 1992, 61(2):114-116.
21. Zhu MY, Juorio AV: Aromatic L-amino acid decarboxylase: bio-
logical characterization and functional role.  Gen Pharmacol
1995, 26(4):681-696.
22. Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC,
Gleave ME, Cox ME, Rennie PS: Comprehensive expression anal-
ysis of l-dopa decarboxylase and established neuroendocrine
markers in neoadjuvant hormone-treated versus varying
Gleason grade prostate tumors.  Hum Pathol 2007,
38(1):161-170.
23. Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitor-
ing of gene expression patterns with a complementary DNA
microarray.  Science 1995, 270(5235):467-470.
24. Velasco AM, Gillis KA, Li Y, Brown EL, Sadler TM, Achilleos M,
Greenberger LM, Frost P, Bai W, Zhang Y: Identification and vali-
dation of novel androgen-regulated genes in prostate can-
cer.  Endocrinology 2004, 145(8):3913-3924.
25. Zhang Y, Akinmade D, Hamburger AW: The ErbB3 binding pro-
tein Ebp1 interacts with Sin3A to repress E2F1 and AR-
mediated transcription.  Nucleic Acids Res 2005,
33(18):6024-6033.
26. Ma AH, Xia L, Desai SJ, Boucher DL, Guan Y, Shih HM, Shi XB,
Devere White RW, Chen HW, Tepper CG, Kung HJ: Male Germ
Cell-Associated Kinase, a Male-Specific Kinase Regulated by
Androgen, Is a Coactivator of Androgen Receptor in Pros-
tate Cancer Cells.  Cancer Res 2006, 66(17):8439-8447.
27. Yan J, Yu CT, Ozen M, Ittmann M, Tsai SY, Tsai MJ: Steroid recep-
tor coactivator-3 and activator protein-1 coordinately regu-
late the transcription of components of the insulin-like
growth factor/AKT signaling pathway.  Cancer Res 2006,
66(22):11039-11046.
28. Beisvag V, Junge FK, Bergum H, Jolsum L, Lydersen S, Gunther CC,
Ramampiaro H, Langaas M, Sandvik AK, Laegreid A: GeneTools--
application for functional annotation and statistical hypothe-
sis testing.  BMC Bioinformatics 2006, 7:470.
29. GeneTools:  [http://www.genetools.no].
30. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC: Molec-
ular cloning and characterization of a novel dopamine recep-
tor (D3) as a target for neuroleptics.  Nature 1990,
347(6289):146-151.
31. Xu LL, Shanmugam N, Segawa T, Sesterhenn IA, McLeod DG, Moul
JW, Srivastava S: A novel androgen-regulated gene, PMEPA1,
located on chromosome 20q13 exhibits high level expression
in prostate.  Genomics 2000, 66(3):257-263.
32. Rae FK, Hooper JD, Nicol DL, Clements JA: Characterization of a
novel gene, STAG1/PMEPA1, upregulated in renal cell carci-
noma and other solid tumors.  Mol Carcinog 2001, 32(1):44-53.
33. Wang M, Kim IG, Steinert PM, McBride OW: Assignment of the
human transglutaminase 2 (TGM2) and transglutaminase 3
(TGM3) genes to chromosome 20q11.2.  Genomics 1994,
23(3):721-722.
34. Dubbink HJ, Verkaik NS, Faber PW, Trapman J, Schroder FH, Romijn
JC: Tissue specific and androgen-regulated expression of
human prostate-specific transglutaminase.  Biochem J 1996,
315 ( Pt 3):901-908.Page 10 of 11
(page number not for citation purposes)
Molecular Cancer 2007, 6:38 http://www.molecular-cancer.com/content/6/1/38Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
35. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE: Androgen receptor
down regulation by small interference RNA induces cell
growth inhibition in androgen sensitive as well as in andro-
gen independent prostate cancer cells.  J Steroid Biochem Mol Biol
2005, 96(3-4):251-258.
36. Geppert M, Archer BT 3rd, Sudhof TC: Synaptotagmin II. A novel
differentially distributed form of synaptotagmin.  J Biol Chem
1991, 266(21):13548-13552.
37. Lania AG, Mantovani G, Spada A: Mechanisms of disease: Muta-
tions of G proteins and G-protein-coupled receptors in endo-
crine diseases.  Nat Clin Pract Endocrinol Metab 2006, 2(12):681-693.
38. Hollmann MW, Strumper D, Herroeder S, Durieux ME: Receptors,
G proteins, and their interactions.  Anesthesiology 2005,
103(5):1066-1078.
39. Perez DM, Karnik SS: Multiple signaling states of G-protein-
coupled receptors.  Pharmacol Rev 2005, 57(2):147-161.
40. Daaka Y: G proteins in cancer: the prostate cancer paradigm.
Sci STKE 2004, 2004(216):re2.
41. Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani
DD, Schulman CC, Carducci MA: Suppression of prostate cancer
induced bone remodeling by the endothelin receptor A
antagonist atrasentan.  J Urol 2003, 169(3):1143-1149.
42. Taub JS, Guo R, Leeb-Lundberg LM, Madden JF, Daaka Y: Bradykinin
receptor subtype 1 expression and function in prostate can-
cer.  Cancer Res 2003, 63(9):2037-2041.
43. Kue PF, Taub JS, Harrington LB, Polakiewicz RD, Ullrich A, Daaka Y:
Lysophosphatidic acid-regulated mitogenic ERK signaling in
androgen-insensitive prostate cancer PC-3 cells.  Int J Cancer
2002, 102(6):572-579.
44. Sivashanmugam P, Tang L, Daaka Y: Interleukin 6 mediates the
lysophosphatidic acid-regulated cross-talk between stromal
and epithelial prostate cancer cells.  J Biol Chem 2004,
279(20):21154-21159.
45. Porter AT, F ACRO, Ben-Josef E: Humoral mechanisms in pros-
tate cancer: A role for FSH.  Urol Oncol 2001, 6(4):131-138.
46. Nambi P, Aiyar N: G protein-coupled receptors in drug discov-
ery.  Assay Drug Dev Technol 2003, 1(2):305-310.
47. Civelli O, Bunzow JR, Grandy DK: Molecular diversity of the
dopamine receptors.  Annu Rev Pharmacol Toxicol 1993,
33:281-307.
48. Gingrich JA, Caron MG: Recent advances in the molecular biol-
ogy of dopamine receptors.  Annu Rev Neurosci 1993, 16:299-321.
49. Sidhu A, Niznik HB: Coupling of dopamine receptor subtypes
to multiple and diverse G proteins.  Int J Dev Neurosci 2000,
18(7):669-677.
50. Zanassi P, Paolillo M, Feliciello A, Avvedimento EV, Gallo V, Schinelli
S: cAMP-dependent protein kinase induces cAMP-response
element-binding protein phosphorylation via an intracellular
calcium release/ERK-dependent pathway in striatal neurons.
J Biol Chem 2001, 276(15):11487-11495.
51. Yan Z, Feng J, Fienberg AA, Greengard P: D(2) dopamine recep-
tors induce mitogen-activated protein kinase and cAMP
response element-binding protein phosphorylation in neu-
rons.  Proc Natl Acad Sci U S A 1999, 96(20):11607-11612.
52. Sadar MD, Hussain M, Bruchovsky N: Prostate cancer: molecular
biology of early progression to androgen independence.
Endocr Relat Cancer 1999, 6(4):487-502.
53. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD,
White FM, Christian RE, Settlage RE, Shabanowitz J, Hunt DF, Weber
MJ: Androgen receptor phosphorylation. Regulation and
identification of the phosphorylation sites.  J Biol Chem 2002,
277(32):29304-29314.Page 11 of 11
(page number not for citation purposes)
